Biophytis (EPA:ALBPS) | WebDisclosure

PRESS RELEASE

published on 04/08/2024 at 23:00, 1 year 11 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA phase 2 clinical study with BIO101 (20-hydroxyecdysone) for obesity treatment, targeting muscle preservation and promising results. Clinical program expected to start mid-2024

Biophytis Obesity Treatment BIO101 OBA Phase 2 Muscle Preservation
PRESS RELEASE

published on 04/08/2024 at 23:00, 1 year 11 months ago

Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone)
Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone). Résultats prometteurs pour traiter la perte musculaire liée à l'obésité. Marché potentiel de 100 milliards de dollars d'ici 2030

Biophytis Étude Clinique BIO101 Obésité Perte Musculaire
BRIEF

published on 04/04/2024 at 23:05, 1 year 11 months ago

Biophytis annonce le succès de son Assemblée Générale du 2 avril 2024

Biophytis Biotechnologie Assemblée Générale Développement Clinique Maladies Liées À L'âge
BRIEF

published on 04/04/2024 at 23:05, 1 year 11 months ago

Biophytis Announces Unanimous Approval in General Meeting

Biophytis Shareholder Approval General Meeting RuvembriTM Age-related Diseases
PRESS RELEASE

published on 04/04/2024 at 23:00, 1 year 11 months ago

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
Biophytis announces all resolutions presented at the combined general meeting on April 2, 2024, have been adopted, including financial delegations. Shareholders' mobilization ensured a quorum of nearly 30%

Shareholders Biophytis General Meeting Resolutions Approval
PRESS RELEASE

published on 04/04/2024 at 23:00, 1 year 11 months ago

RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 2 AVRIL 2024
Biophytis annonce l'adoption de toutes les résolutions lors de son Assemblée Générale Mixte du 2 avril 2024. Les résultats sont disponibles sur leur site. Détails sur les activités et avertissement inclus

Biophytis Développement Biotechnologie Assemblée Générale Résultats
REGULATED PRESS RELEASE

published on 04/04/2024 at 23:00, 1 year 11 months ago

RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 2 AVRIL 2024
Biophytis annonce l'approbation de toutes les résolutions présentées lors de son Assemblée Générale Mixte. Les détails des votes sont disponibles en ligne. En savoir plus sur BIOPHYTIS et ses candidats-médicaments

Biophytis Développement Assemblée Générale Resolutions Candidats-médicaments
REGULATED PRESS RELEASE

published on 04/04/2024 at 23:00, 1 year 11 months ago

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
Biophytis announces approval of all resolutions at the Combined General Meeting held on April 2, 2024, with significant shareholder turnout. The Company specializes in therapeutics for age-related diseases

Shareholders Biophytis Therapeutics Combined General Meeting Age-related Diseases
BRIEF

published on 03/22/2024 at 07:05, 2 years ago

Biophytis dévoile son étude de phase 3 sur le traitement de la sarcopénie

Biophytis Sarcopénie Ruvembri Étude De Phase 3 ICFSR
BRIEF

published on 03/22/2024 at 07:05, 2 years ago

Biophytis Unveils Phase 3 Sarcopenia Treatment Protocol

Biophytis Clinical Research RuvembriTM Sarcopenia Phase 3 Study

Published on 03/24/2026 at 07:00, 44 minutes ago

Panther Minerals Earns In Under Rubidium Ridge Project Option
Published on 03/24/2026 at 07:00, 44 minutes ago

Panther Completes Acquisition of Rubidium Ridge Project
Published on 03/24/2026 at 00:55, 6 hours 49 minutes ago

BTU Closes Oversubscribed Financing
Published on 03/23/2026 at 22:40, 9 hours 4 minutes ago

Troubadour Announces Withdrawal of Non-Brokered Private Placements
Published on 03/23/2026 at 22:30, 9 hours 14 minutes ago

Gregory J. Leia Sells Shares in Waskahigan Oil & Gas Corp

View all ACCESSWIRE

Published on 03/24/2026 at 07:30, 14 minutes ago

Drägerwerk AG & Co. KGaA: Dräger with good order development, record net sales and significant increase in net profit in fiscal year 2025 – third dividend increase in a row
Published on 03/24/2026 at 07:23, 20 minutes ago

INDUS confirms a solid financial year 2025 – Proposed dividend of EUR 1.30 exceeds previous year
Published on 03/24/2026 at 07:00, 43 minutes ago

After strong fourth quarter, INFICON closes 2025 at record sales level
Published on 03/24/2026 at 07:00, 43 minutes ago

Curatis: Double-digit revenue growth in 2025 and major milestones for corticorelin achieved
Published on 03/24/2026 at 07:00, 43 minutes ago

MCH Group Reports Profitability Improvement in 2025

View all EQS

Published on 03/24/2026 at 07:30, 14 minutes ago

Gimv secures new EUR 400 million revolving credit facility to support accelerated growth ambitions
Published on 03/24/2026 at 07:30, 14 minutes ago

Gimv verzekert zich van een nieuwe Revolving Credit Facility van EUR 400 miljoen ter ondersteuning van de versnelde groeiambities
Published on 03/23/2026 at 19:08, 12 hours 36 minutes ago

Reporting on share buyback transactions carried out between March 16 and March 20, 2026
Published on 03/23/2026 at 19:08, 12 hours 36 minutes ago

Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 16 et le 20 mars 2026
Published on 03/23/2026 at 18:37, 13 hours 6 minutes ago

ALTAREA : Déclaration d’opérations sur actions propres

View all LES ECHOS COMFI WIRE

News